The overall goal of the University of Kansas Alzheimer's Disease Core Center (KU ADCC) Neuromaging Core is to enhance the neuroimaging infrastructure and facilitate increased research in aging and Alzheimer's disease for researchers at the University of Kansas and nearby institutions. The Neuroimaging Core builds on the established resources of the (i) KU Hoglund Brain Imaging Center that brings together, in a specialized research building, a unique array of human (3 Tesla) and animal (9.4 Tesla) MRI and cortical (151 channel) and fetal (83 channel) magnetoencephalography (MEG), and the (ii) KU Hospital that provides positron emission tomography as well as a strong faculty of imaging scientists with outstanding experience across the modalities. Accordingly, the Neuroimaging Core is ideally resourced to support current and future investigators who use imaging as a research tool. This goal will be achieved through three specific aims that provide (i) state-of-the-art imaging facilities and professional neuroimaging support, (ii) advanced education in imaging sciences and (iii) novel imaging approaches to AD investigators of the University of Kansas, the state of Kansas, and the Kansas City metropolitan area.
The Specific Aims of the KU ADCC Neuroimaging Core are Aim 1. Provide an integrated imaging environment with advanced scientific support and subsidized scans for AD research Aim 2. Provide advanced training, and education in imaging for ADCC investigators.
Aim 3. Develop novel imaging techniques for studies in AD.

Public Health Relevance

Neuroimaging provides a non-invasive means to measure structure and function of the living human brain. The Neuroimaging Core will support scientists investigating Alzheimer's and other neurodegenerative diseases of aging by providing access to state-of-the-art imaging, education and training in imaging modalities, and novel imaging methods.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
1P30AG035982-01A1
Application #
8295041
Study Section
Special Emphasis Panel (ZAG1-ZIJ-5 (M2))
Project Start
Project End
Budget Start
2011-08-15
Budget End
2012-06-30
Support Year
1
Fiscal Year
2011
Total Cost
$80,433
Indirect Cost
Name
University of Kansas
Department
Type
DUNS #
016060860
City
Kansas City
State
KS
Country
United States
Zip Code
66160
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Besser, Lilah; Kukull, Walter; Knopman, David S et al. (2018) Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set. Alzheimer Dis Assoc Disord 32:351-358
Morris, Jill K; Piccolo, Brian D; Shankar, Kartik et al. (2018) The serum metabolomics signature of type 2 diabetes is obscured in Alzheimer's disease. Am J Physiol Endocrinol Metab 314:E584-E596
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325
Ptomey, Lauren T; Szabo, Amanda N; Willis, Erik A et al. (2018) Changes in cognitive function after a 12-week exercise intervention in adults with Down syndrome. Disabil Health J 11:486-490
Kamara, Dennis M; Gangishetti, Umesh; Gearing, Marla et al. (2018) Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. J Alzheimers Dis 62:1815-1826
Tse, Kai-Hei; Cheng, Aifang; Ma, Fulin et al. (2018) DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. Alzheimers Dement 14:664-679
Kaur, Antarpreet; Edland, Steven D; Peavy, Guerry M (2018) The MoCA-Memory Index Score: An Efficient Alternative to Paragraph Recall for the Detection of Amnestic Mild Cognitive Impairment. Alzheimer Dis Assoc Disord 32:120-124

Showing the most recent 10 out of 333 publications